Harmony Biosciences Q4 2023 revenue $168.4M, guides 2024 revenue $700-720M

Harmony Biosciences Holdings, Inc.

2023-FY EPS reported $2.13 revenue$582,022,000

WAKIX net revenue $168.4M in Q4 2023 (+31% YoY); full year $582.0M (+33%).
GAAP diluted EPS $0.45 vs $0.79 YoY; non-GAAP adjusted EPS $0.73 vs $1.01.
FDA granted priority review for WAKIX in pediatric narcolepsy; PDUFA June 21, 2024.
2024 net product revenue guidance $700-720M, up from ~$582M in 2023.
Repurchased 3.2M shares for $100M in 2023; $150M remaining authorization.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Harmony Biosciences Holdings, Inc. reported financial results for the quarter and year ended December 31, 2023.

Period: the quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Harmony Biosciences Holdings, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Harmony Biosciences Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-001465

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.